Patients with unresectable metastatic colorectal cancer (mCRC) that has spread only to the liver experienced the greatest improvement in progression-free survival in the liver from the addition of SIR-Spheres Y-90 resin microspheres to a current first-line chemotherapy regimen, according to new data from the SIRFLOX study presented at the European Society for Medical Oncology (ESMO) 17th World Congress of Gastrointestinal Cancer (WCGIC; 1–4 July, Barcelona, Spain).
Twelve-month results from the VeClose trial have demonstrated cyanoacrylate adhesive (CAE) is non-inferior to radiofrequency ablation (RFA) for the treatment of incompetent great saphenous veins.
After obtaining a PhD in Biophysics in London, UK, Janet Powell, professor of Vascular Biology & Medicine at Imperial College, London, studied medicine in the United States, before returning to the UK where she completed clinical training in pathology, specialising in cardiovascular risk. In this interview, Powell tells why the cause and management of abdominal aortic aneurysms are her major research interest and speaks about her early career, her mentors, the IMPROVE randomised controlled trial, and also her interests outside medicine.
David Cull, Greenville, USA, writes that vascular access placement in the elderly needs to take into account patients’ physiological age in an effort to predict survival.
Open vena caval surgery is rare. It is mainly performed for oncological indications when the inferior vena cava is involved by an adjacent tumour. One of the most common malignancies that affect the inferior vena cava is renal cell carcinomas of the kidneys with thrombi that extend into the inferior vena cava lumen or invade its wall. This occurs more commonly on the right side due to shorter renal vein. Removal of these tumors and accompanying thrombi provide survival benefits for those patients. Additionally, among the non-oncological indications of inferior vena cava surgery is the occasional need to remove inferior vena cava filters that have been inserted to prevent pulmonary emboli and could not be retrieved through conventional endovascular approaches.
Medtronic has announced that the first two European patient cases with the Endurant Evo AAA stent graft system were successfully performed by Hence Verhagen, chief of vascular surgery and his team at the Erasmus Medical Center in Rotterdam, the Netherlands.
A study utilising preoperative anatomical severity grading in patients undergoing abdominal aortic aneurysm repair has shown that high scores correlate with increased total cost and resource utilisation and the need for adjunctive procedures during endovascular aneurysm repair (EVAR). Because of these adjunctive techniques, the cost of EVAR was US$9,100 higher than open repair in patients with complex anatomies.
Lombard Medical announced on 30 July 2015 the acquisition of Silicon Valley-based Altura Medical, a privately-held, venture-backed company that has developed an innovative ultra-low profile endovascular stent graft technology that, according to Lombard, offers a simple and predictable solution for the treatment of standard abdominal aortic aneurysm anatomies.
Essential Medical has successfully commenced EU clinical studies using its Manta large bore vascular closure device, a vascular closure device designed to seal both 14F and 18F large bore femoral punctures.
Results from the 9th Annual Survey on Observational Research conducted by Continuum Clinical suggest that the pharmaceutical, biotech, and medical device industries are aware of the benefits of observational research in better understanding the real world value of their products. However, they also show that there is continued need to improve the design and implementation of the studies.
Vascutek Ltd has reached a new milestone with the successful implantation of the 1000th Fenestrated Anaconda™ custom AAA stent graft system. The 1000th implant was undertaken by Professor Dominique Midy and Dr Julien Morin from Bordeaux, France on a 62-year-old male who is recovering well following the procedure. The design of the Fenestrated Anaconda™ device for this particular patient was a bifurcated stent graft with 4 fenestrations.
At the International Symposium on Endovascular Therapeutics (SITE; 24–27 June, Barcelona, Spain) Gustavo S Oderich, Mayo Clinic, Rochester, USA, said that there are no definitive studies supporting routine use of embolic protection devices in superficial femoral artery interventions. However, he stated that these devices prevent embolisation during complex procedures.
The first patient has been enrolled and treated in TriVascular Technology’s LUCY study (TriVascular evaluation of females who are underrepresented candidates for abdominal aortic aneurysm sepair).
CREST (Carotid Revascularization Endarterectomy vs Stent Trial) has demonstrated a higher periprocedural stroke and death rate among patients randomised to carotid artery stenting (4.4%) than carotid endarterectomy (2.3%, p=0.005). In previous publications, in an attempt to identify high-risk groups, it has been noted that patients who were older than 70 years did better with carotid endarterectomy than with angioplasty and stenting (p=0.02). In another publication it was noted that women undergoing carotid stenting had a higher event rate than women undergoing carotid endarterectomy.
In July 2015, Jotec received CE mark approval for an enhanced version of the E-vita Thoracic 3G Stent Graft System. According to the company, E-vita Thoracic 3G features an innovative catheter technology “guaranteeing ultimate performance and representing Jotec’s clear commitment to offer cutting-edge technology for best patient care”.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos